Barely Significant
← all excerpts

First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.

World J Gastroenterol · 2017 · PMC5743510 · PMID 29307999

Europe PMCDOI
1
hedged sentence
0.0900
closest p · 1.8× alpha
0.0900
boldest claim

The sentences

an increasing trendP = 0.09so close (0.05 < p ≤ 0.1)
An increasing trend toward a higher CSR was observed in the dexlansoprazole group at day 7 (55.3% vs 36.8%, P = 0.09).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.